Holen Sie sich die Stockscreener-App
77.74
10.61%
7.46
Handel nachbörslich:
77.00
-0.74
-0.95%
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Will Mirum Pharmaceuticals Inc. stock pay special dividends2025 Macro Impact & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
How Mirum Pharmaceuticals Inc. stock compares to growth peersMarket Growth Summary & Low Drawdown Momentum Trade Ideas - ulpravda.ru
Mirum Pharmaceuticals Surges Following Strategic Moves and Analyst Ratings - timothysykes.com
Is Mirum Pharmaceuticals Inc. stock supported by strong fundamentalsM&A Rumor & High Accuracy Trade Signal Alerts - ulpravda.ru
Mirum Pharmaceuticals files patent suits to block generic Livmarli approval By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals files patent suits to block generic Livmarli approval - Investing.com
Mirum Pharmaceuticals: Bluejay Acquisition Boost - StocksToTrade
Mirum Files Patent Suits to Block Livmarli Generics - TipRanks
Mirum secures $68.5 million in private placement ahead of acquisition By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals stock hits all-time high at 78.55 USD - Investing.com
Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target - ts2.tech
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Up 8.9% Following Analyst Upgrade - MarketBeat
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX - Investing News Network
Mirum Pharmaceuticals to raise $68.5M in private placement with TCGX - MSN
Mirum Pharmaceuticals announces additional private placement financing with TCGX - marketscreener.com
Mirum secures $68.5 million in private placement ahead of acquisition - Investing.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $140.00 - MarketBeat
Mirum Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
Can Mirum Pharmaceuticals Inc. stock reach $100 price target2025 Investor Takeaways & Verified Momentum Stock Ideas - DonanımHaber
Mirum Pharmaceuticals stock price target raised to $140 by Citizens - Investing.com Canada
Citizens raises Mirum Pharmaceuticals stock price target to $140 on pipeline confidence - Investing.com Canada
Market Recap: Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryTrade Risk Report & Weekly Hot Stock Watchlists - ulpravda.ru
Is Mirum Pharmaceuticals Inc. stock trading at a premium valuationJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - ulpravda.ru
What hedge fund activity signals for Mirum Pharmaceuticals Inc. stockQuarterly Profit Summary & Low Risk Entry Point Guides - ulpravda.ru
Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? - Yahoo Finance
Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryGold Moves & Free Fast Gain Swing Trade Alerts - Улправда
Stifel Nicolaus Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
Why Mirum Pharmaceuticals Stock is Climbing - TipRanks
Baird lifts Mirum Pharmaceuticals, Inc. (MIRM) price target on Bluejay Therapeutics acquisition - MSN
The week in pharma: action, reaction and insight – week to December 12 - The Pharma Letter
Eventide Asset Management LLC Has $134.22 Million Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by BVF Inc. IL - MarketBeat
Boone Capital Management LLC Has $32.64 Million Stock Position in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened - MSN
Rx Rundown: Pfizer, Mirum Pharmaceuticals, Novartis and more - Medical Marketing and Media
Mirum Pharmaceuticals stock price target raised to $110 by Raymond James - Investing.com Canada
Baird Lifts Mirum Pharmaceuticals, Inc. (MIRM) Price Target on Bluejay Therapeutics Acquisition - Insider Monkey
Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition - Insider Monkey
What is HC Wainwright's Forecast for MIRM FY2025 Earnings? - MarketBeat
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' - MSN
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2025 - BioSpace
Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback - Yahoo Finance
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - MSN
Mirum Pharmaceuticals (Nasdaq: MIRM) approves stock option and RSU inducement grants for 8 new hires - Stock Titan
Mirum Pharmaceuticals stock price target raised to $100 by Leerink - Investing.com Canada
Trading Systems Reacting to (MIRM) Volatility - news.stocktradersdaily.com
Baird Maintains Mirum Pharmaceuticals (MIRM) Outperform Recommendation - Nasdaq
Mirum adds to liver disease pipeline with Bluejay takeout: Deals Report - biocentury.com
One Peninsula drug maker to buy another for up to $820 million around drug cut by Novartis - The Business Journals
Mirum Pharmaceuticals' Bluejay Acquisition Expands Liver Disease Pipeline, Morgan Stanley Says - marketscreener.com
Mirum Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald - Yahoo Finance
Mirum to buy Bluejay for up to $820m in rare liver disease push - Yahoo Finance
Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $95 From $81, Keeps Overweight Rating - marketscreener.com
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Jump Financial LLC - MarketBeat
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - BioSpace
Five things for pharma marketers to know for Tuesday, December 9, 2025 - Medical Marketing and Media
Baird raises Mirum Pharmaceuticals stock price target to $88 on Bluejay acquisition - Investing.com Canada
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):